These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38947360)

  • 1. Dupilumab Therapy Modulates Circulating Inflammatory Mediators in Patients with Prurigo Nodularis.
    Bao A; Ma E; Cornman H; Kambala A; Manjunath J; Kollhoff AL; Imo BU; Kwatra MM; Kwatra SG
    JID Innov; 2024 Jul; 4(4):100281. PubMed ID: 38947360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab for the Treatment of Prurigo Nodularis.
    Alkhaleefa A; Woo TE; Parsons L
    Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
    Liao V; Cornman HL; Ma E; Kwatra SG
    Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical review of dupilumab for adult patients with prurigo nodularis.
    Biazus Soares G; Yosipovitch G
    Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
    Fang HY; Lian CH
    J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.
    Belzberg M; Alphonse MP; Brown I; Williams KA; Khanna R; Ho B; Wongvibulsin S; Pritchard T; Roh YS; Sutaria N; Choi J; Jedrych J; Johnston AD; Sarkar K; Vasavda C; Meixiong J; Dillen C; Bondesgaard K; Paolini JF; Chen W; Corcoran D; Devos N; Kwatra MM; Chien AL; Archer NK; Garza LA; Dong X; Kang S; Kwatra SG
    J Invest Dermatol; 2021 Sep; 141(9):2208-2218.e14. PubMed ID: 33771530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
    Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
    JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
    Husein-ElAhmed H; Steinhoff M
    J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation.
    Cornman HL; Manjunath J; Reddy SV; Adams J; Rajeh A; Samuel C; Bao A; Zhao R; Ma EZ; Shumsky J; Pritchard TW; Imo BU; Kollhoff AL; Lee KK; Lu W; Yossef S; Kwatra MM; Kwatra SG
    Sci Rep; 2024 Apr; 14(1):8098. PubMed ID: 38582943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab Treatment for Prurigo Nodularis and Pruritis.
    Tanis R; Ferenczi K; Payette M
    J Drugs Dermatol; 2019 Sep; 18(9):940-942. PubMed ID: 31524352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
    Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT
    Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Stroke Asymmetric Prurigo Nodularis Responding to Dupilumab Treatment: A Case Report.
    Sammarra I; Bennardo L; Provenzano E; Patruno C; Nisticò SP
    Brain Sci; 2022 May; 12(5):. PubMed ID: 35624992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab as promising treatment for prurigo nodularis: current evidences.
    Toffoli L; Farinazzo E; Zelin E; Agozzino M; Dianzani C; Di Meo N; Nan K; Zalaudek I; Conforti C
    J Dermatolog Treat; 2022 May; 33(3):1306-1311. PubMed ID: 33588666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab.
    Tsoi LC; Hacini-Rachinel F; Fogel P; Rousseau F; Xing X; Patrick MT; Billi AC; Berthier CC; Kahlenberg JM; Lazzari A; Wiegmann H; Ständer S; Piketty C; Julia V; Krishnaswamy JK; Gudjonsson JE
    J Allergy Clin Immunol; 2022 Apr; 149(4):1329-1339. PubMed ID: 34857395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis.
    Zhang Z; Li S; Wang Y; Zhao J
    An Bras Dermatol; 2023; 98(4):440-448. PubMed ID: 36966024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications.
    Agrawal D; Sardana K; Mathachan SR; Bhardwaj M; Ahuja A; Jain S
    J Cosmet Dermatol; 2022 Sep; 21(9):4009-4015. PubMed ID: 34965028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching.
    Shao Y; Zhu Y; Xiao Z; Shen Y; Dai B; Tang H; Wang D
    Exp Dermatol; 2023 Jan; 32(1):30-40. PubMed ID: 36134503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical evaluation of nemolizumab for prurigo nodularis.
    Brooks SG; Yosipovitch G
    Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab for prurigo nodularis: Case series and review of the literature.
    Holm JG; Agner T; Sand C; Thomsen SF
    Dermatol Ther; 2020 Mar; 33(2):e13222. PubMed ID: 31917498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prurigo Nodularis: Review and Emerging Treatments.
    Leis M; Fleming P; Lynde CW
    Skin Therapy Lett; 2021 May; 26(3):5-8. PubMed ID: 34077168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.